OUR IMPACT ON HEALTH
The translational research and development activities at the LSI are having a large impact on Human Health and Wellness. Researchers at the LSI have been responsible for bringing targeted new drugs to the market and into clinical trials. Teams are also focused on impacting healthcare by changing the way it is practiced through the implementation of molecular based technologies to better predict health and disease.
Impact on Drug Development
Recent discoveries at the LSI are garnering interest in medical circles around the world. The translational activities at the LSI of Dr. Cullis have resulted in the development of a series of new therapeutics. For example, several LSI teams are helping to bring new drugs into the market including few for the treatment of cancer and its complications, cystic fibrosis and a genetic drug designed to prevent organ failure.
Approximately 5% of all hospital admissions are associated with adverse drug reactions (ADRs). In North America this corresponds to over 2 million serious ADRs/ year leading to over 100,000 deaths. The New England Healthcare Institute (NEHI: 2009) estimated that the cost of drug-related morbidity, including poor adherence could result in as much as $290 billion per year in avoidable medical spending or 13 percent of total health care expenditures. The treatment of ADR was more than that for treating obesity and diabetes in the USA. Aside from dangers resulting from ADR, more than 50% of prescribed drugs do not work on the patients they are prescribed for, due to genetic diversity.